Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815347 · ClinicalTrials.gov registry record · Phase 2
Bosentan for Poorly Controlled Asthma
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00815347 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 11 participants.
The verdict
NCT00815347, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Hypothesis: The endothelin-1 receptor antagonist, bosentan when added to the treatment of asthma patients who are symptomatic despite the use of controller therapy will improve asthma symptoms and physiology. Twenty patients with a diagnosis of asthma, between the ages of 21 and 70 who are symptomatic despite the use of at least one controller medication will be randomized to either placebo or active medication for an 8 week period (initial 4 weeks is at 1/2 of final dose as per package insert and FDA approval). Measures of lung function and symptoms will be recorded. Patients will then cross over, so that patients initially on placebo will receive active drug for 8 weeks and those initially on active drug will receive placebo. The same endpoints will be measured. The acute bronchodilator effects of the drug will also be tested on the first day of therapy at the full therapeutic dose.
Interventions
- DRUG placebo
- DRUG bosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815347
The ClinicalTrials.gov registry entry for NCT00815347 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00815347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815347 about?
NCT00815347 is a clinical study titled "Bosentan for Poorly Controlled Asthma". Hypothesis: The endothelin-1 receptor antagonist, bosentan when added to the treatment of asthma patients who are symptomatic despite the use of controller therapy will improve asthma symptoms and physiology. Twenty patients with a diagnosis of asthma, between the ages of 21 and 70 who are symptoma...
What is the current status of trial NCT00815347?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00815347?
The interventions under investigation include: placebo (DRUG), bosentan (DRUG).
Who is sponsoring clinical trial NCT00815347?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.